Tyra Biosciences (NASDAQ:TYRA – Free Report) had its target price raised by Wedbush from $53.00 to $57.00 in a report released on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.
A number of other equities analysts have also commented on TYRA. Piper Sandler reissued an “overweight” rating and issued a $56.00 price target on shares of Tyra Biosciences in a report on Tuesday, September 8th. Oppenheimer reiterated an “outperform” rating and set a $40.00 price target (down from $50.00) on shares of Tyra Biosciences in a research report on Tuesday, September 22nd. William Blair raised shares of Tyra Biosciences to a “strong-buy” rating in a research note on Wednesday, September 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of Tyra Biosciences in a report on Thursday, September 10th. Finally, HC Wainwright decreased their target price on shares of Tyra Biosciences from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $47.40.
Get Our Latest Research Report on TYRA
Tyra Biosciences Stock Performance
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07). As a group, research analysts predict that Tyra Biosciences will post -2.77 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jupiter Topco LLC bought a new position in Tyra Biosciences during the 2nd quarter valued at about $139,161,000. Janus Henderson Group PLC increased its position in Tyra Biosciences by 32.5% during the 1st quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock valued at $148,867,000 after buying an additional 955,147 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Tyra Biosciences in the 2nd quarter valued at $96,841,000. 5AM Venture Management LLC purchased a new position in Tyra Biosciences during the 2nd quarter worth approximately $32,875,778. Finally, Jennison Associates LLC acquired a new position in shares of Tyra Biosciences in the 1st quarter valued at about $24,222,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.
More Tyra Biosciences News
These are some of the TYRA news items that stood out recently:
- Positive Sentiment: HC Wainwright kept its Buy rating and $27 price target, while a separate report described analysts as bullish on TYRA. The target suggests potential upside from the recently cited $20.02 price, though it is not a guarantee. Analysts Are Bullish on Top Healthcare Stocks: Claritev (CTEV), Tyra Bioscience (TYRA)
- Neutral Sentiment: Certain restricted stock units are covered by a lock-up agreement ending November 13. The expiry could allow shares to be sold, but the report does not indicate that holders plan to sell. Restricted Stock Unit Lock-Up Agreement
- Negative Sentiment: Tyra’s Q3 loss widened, and it missed the earnings-per-share consensus. Reports also noted shares fell below their 50-day moving average after the disappointing results, reinforcing near-term concerns. Tyra Biosciences’ Q3 Net Loss Widens Stock Breaks Below Fifty Day Moving Average on Disappointing Earnings
Tyra Biosciences Company Profile
Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.
Featured Stories
- Five stocks we like better than Tyra Biosciences
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
